EAACI Congress 2024

Back
31 May - 03 June 2024 Valencia, Spain

Design of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tezepelumab in adult patients with severe chronic rhinosinusitis with nasal polyposis (WAYPOINT)

Sunday 02 Jun, 12:00 PM - 12:00 PM Valencia, Spain